Patient Factors Influencing the Prescribing of Lipid Lowering Drugs for Primary Prevention of Cardiovascular Disease in UK General Practice: A National Retrospective Cohort Study

被引:46
|
作者
Wu, Jianhua [1 ]
Zhu, Shihua [2 ]
Yao, Guiqing Lily [3 ]
Mohammed, Mohammed A. [2 ]
Marshall, Tom [2 ]
机构
[1] Univ London, Ctr Environm & Prevent Med, Barts & London Sch Med & Dent, London, England
[2] Univ Birmingham, Sch Publ Hlth & Populat Sci, Birmingham, W Midlands, England
[3] Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England
来源
PLOS ONE | 2013年 / 8卷 / 07期
关键词
CORONARY-HEART-DISEASE; MULTIVARIATE PREDICTION; EUROPEAN GUIDELINES; HEALTH-CARE; CHOLESTEROL; RISK; HYPERCHOLESTEROLEMIA; UNDERTREATMENT; POPULATION; MANAGEMENT;
D O I
10.1371/journal.pone.0067611
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Guidelines indicate eligibility for lipid lowering drugs, but it is not known to what extent GPs' follow guidelines in routine clinical practice or whether additional clinical factors systematically influence their prescribing decisions. Methods: A retrospective cohort analysis was undertaken using electronic primary care records from 421 UK general practices. At baseline (May 2008) patients were aged 30 to 74 years, free from cardiovascular disease and not taking lipid lowering drugs. The outcome was prescription of a lipid lowering drug within the next two years. The proportions of eligible and ineligible patients prescribed lipid lowering drugs were reported and multivariable logistic regression models were used to investigate associations between age, sex, cardiovascular risk factors and prescribing. Results: Of 365,718 patients with complete data, 13.8% (50,558) were prescribed lipid lowering drugs: 28.5% (21,101/74,137) of those eligible and 10.1% (29,457/291,581) of those ineligible. Only 41.7% (21,101/50,558) of those prescribed lipid lowering drugs were eligible. In multivariable analysis prescribing was most strongly associated with increasing age (OR for age >= 65 years 4.21; 95% CI 4.05-4.39); diabetes (OR 4.49; 95% CI 4.35-4.64); total cholesterol level >= 7 mmol/L (OR 2.20; 95% CI 2.12-2.29); and >= 4 blood pressure measurements in the past year (OR 4.24; 95% CI 4.06-4.42). The predictors were similar in eligible and ineligible patients. Conclusions: Most lipid lowering drugs for primary prevention are prescribed to ineligible patients. There is underuse of lipid lowering drugs in eligible patients.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Under-prescribing of Prevention Drugs and Primary Prevention of Stroke and Transient Ischaemic Attack in UK General Practice: A Retrospective Analysis
    Turner, Grace M.
    Calvert, Melanie
    Feltham, Max G.
    Ryan, Ronan
    Fitzmaurice, David
    Cheng, K. K.
    Marshall, Tom
    [J]. PLOS MEDICINE, 2016, 13 (11)
  • [2] Patient and Other Factors Influencing the Prescribing of Cardiovascular Prevention Therapy in the General Practice Setting With and Without Nurse Assessment
    Mohammed, Mohammed A.
    El Sayed, Charlotte
    Marshall, Tom
    [J]. MEDICAL DECISION MAKING, 2012, 32 (03) : 498 - 506
  • [3] Dental consultations in UK general practice and antibiotic prescribing rates: a retrospective cohort study
    Cope, Anwen L.
    Chestnutt, Ivor G.
    Wood, Fiona
    Francis, Nick A.
    [J]. BRITISH JOURNAL OF GENERAL PRACTICE, 2016, 66 (646): : E329 - E336
  • [4] Management of lipid-lowering therapy in patients with cardiovascular events in the UK: a retrospective cohort study
    Danese, Mark D.
    Gleeson, Michelle
    Kutikova, Lucie
    Griffiths, Robert I.
    Khunti, Kamlesh
    Seshasai, Sreenivasa Rao Kondapally
    Ray, Kausik K.
    [J]. BMJ OPEN, 2017, 7 (05):
  • [5] FACTORS INFLUENCING STATIN PRESCRIBING IN HOSPITALIZED PATIENTS AFTER A CARDIOVASCULAR EVENT: A RETROSPECTIVE COHORT STUDY
    Scotti, Stefano
    Olmastroni, Elena
    Galimberti, Federica
    Catapano, Alberico
    Casula, Manuela
    [J]. ATHEROSCLEROSIS, 2024, 395
  • [6] Statin prescribing for prevention of cardiovascular disease amongst people with severe mental illness: Cohort study in UK primary care
    Blackburn, R.
    Osborn, D.
    Walters, K.
    Nazareth, I.
    Petersen, I.
    [J]. SCHIZOPHRENIA RESEARCH, 2018, 192 : 219 - 225
  • [7] Effect of Lipid-Lowering Drugs on Renal and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Dyslipidemia: A Retrospective Cohort Study
    Lin, Yi-Chih
    Tsao, Hsiao-Mei
    Lai, Tai-Shuan
    Chen, Yi-Ting
    Chou, Yu-Hsiang
    Lin, Shuei-Liong
    Chen, Yung-Ming
    Hung, Kuan-Yu
    Tu, Yu-Kang
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 114 (06) : 1366 - 1374
  • [8] Identifying individuals for primary cardiovascular disease prevention in UK general practice: priorities and resource implications
    Holt, Tim A.
    Thorogood, Margaret
    Griffiths, Frances
    Munday, Stephen
    Stables, David
    [J]. BRITISH JOURNAL OF GENERAL PRACTICE, 2008, 58 (552): : 495 - 498
  • [9] Cardiovascular risk factors and disease in general practice: results of the Nijmegen Cohort Study
    Bakx, JC
    Van den Hoogen, HJM
    Van den Bosch, WJHM
    Thien, T
    van Weel, C
    [J]. BRITISH JOURNAL OF GENERAL PRACTICE, 2002, 52 (475): : 135 - 137
  • [10] Aspirin for Primary Prevention of Cardiovascular Disease in Diabetes Mellitus - A Retrospective Cohort Study in Taiwan
    Huang, Ching-Ying
    Lin, Shun-Jin
    Chen, Wei-Hua
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 245 - 246